{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:56:31Z","timestamp":1781139391479,"version":"3.54.1"},"reference-count":20,"publisher":"Georg Thieme Verlag KG","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"abstract":"<jats:p>Percutaneous left atrial appendage occlusion (pLAAO) is increasingly being adopted as an alternative to non-vitamin K antagonist oral anticoagulants (NOACs) for patients with atrial fibrillation. However, the current evidence does not justify this enthusiasm. Key limitations include wide non-inferiority margins in some of the trials, inclusion of components in the primary efficacy endpoint that are not directly influenced by pLAAO, making non-inferiority easier to achieve, limited statistical power to detect differences in ischemic stroke or systemic embolism, and an overstated bleeding advantage.<\/jats:p>","DOI":"10.1055\/a-2862-6722","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:41:46Z","timestamp":1778107306000},"source":"Crossref","is-referenced-by-count":0,"title":["Left Atrial Appendage Closure Lacks Sufficient Evidence for Routine Use"],"prefix":"10.1055","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7796-8701","authenticated-orcid":false,"given":"Mohammed","family":"Ruzieh","sequence":"additional","affiliation":[{"name":"Bluhm Cardiovascular Institute, Northwestern University, United States","department":["Feinberg School of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Foy","sequence":"additional","affiliation":[{"name":"Beebe Healthcare Hospital, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mandrola","sequence":"additional","affiliation":[{"name":"Baptist Healthcare System Inc, United States","department":["Louisville Cardiology Group"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"09","key":"ref2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1055\/a-2469-4896","article-title":"An international consensus practical guide on left atrial appendage closure for the non-implanting physician: executive summary","volume":"125","author":"T Potpara","year":"2025","journal-title":"Thromb Haemost"},{"issue":"13","key":"ref4","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa2513310","article-title":"Left atrial appendage closure or medical therapy in atrial fibrillation","volume":"394","author":"U Landmesser","year":"2026","journal-title":"N Engl J Med"},{"issue":"24","key":"ref5","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"V Y Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"ref6","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation","volume":"75","author":"P Osmancik","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"ref7","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa2408308","article-title":"Left atrial appendage closure after ablation for atrial fibrillation","volume":"392","author":"O M Wazni","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.123.067312","article-title":"Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation","volume":"149","author":"S R Kapadia","year":"2024","journal-title":"Circulation"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"ref10","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial","volume":"312","author":"V Y Reddy","year":"2014","journal-title":"JAMA"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"D R Holmes Jr","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1212\/WNL.0b013e3182a08d59","article-title":"An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke","volume":"81","author":"D M Kent","year":"2013","journal-title":"Neurology"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1055\/a-2434-9244","article-title":"The 2024 European Society of Cardiology guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician's perspective","volume":"124","author":"T Potpara","year":"2024","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1055\/a-2595-5575","article-title":"Patient care pathways and risk assessments in patients with atrial fibrillation: a comparison of Asian versus non-Asian cohorts","volume":"125","author":"H-C Chang","year":"2025","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"S J Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"20","key":"ref18","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for prevention of stroke after embolic stroke of undetermined source","volume":"380","author":"H-C Diener","year":"2019","journal-title":"N Engl J Med"},{"issue":"13","key":"ref19","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"J I Weitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"ref20","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"R G Hart","year":"2018","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"107189","DOI":"10.1016\/j.clineuro.2022.107189","article-title":"Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: a prospective study","volume":"215","author":"S Chen","year":"2022","journal-title":"Clin Neurol Neurosurg"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"J S Healey","year":"2024","journal-title":"N Engl J Med"},{"issue":"01","key":"ref23","first-page":"a2300235","article-title":"Apixaban versus aspirin for embolic stroke of undetermined source","volume":"3","author":"T Geisler","year":"2024","journal-title":"NEJM Evid"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial","volume":"331","author":"H Kamel","year":"2024","journal-title":"JAMA"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2862-6722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:58:03Z","timestamp":1781135883000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2862-6722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":20,"URL":"https:\/\/doi.org\/10.1055\/a-2862-6722","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}